Gene therapy treatment increasing body’s signal for new blood vessel growth shows promise
Long Beach, Calif. – May 2, 2024 – Final 12-month data from the EXACT trial demonstrates safety and efficacy results for a vascular endothelial growth factor (VEGF) gene therapy treatment for patients who have advanced coronary artery disease (CAD). The late-breaking results were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.
CAD, also known as coronary heart disease or ischemic heart disease, affects about 20.5 million U.S. adults – making it the most common type of heart disease in the ...
















